skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Review

(2487) Views  (685) Full article downloads

Authors: Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, et al

Published Date June 2010 Volume 2010:4 Pages 117 - 126
DOI: http://dx.doi.org/10.2147/DDDT.S6627

Clemens Warnke1, Heinz Wiendl2, Hans-Peter Hartung1, Olaf Stüve3, Bernd C Kieseier1

1Department of Neurology, Heinrich-Heine University Düsseldorf, Germany; 2Department of Neurology – Inflammatory Disorders of the Nervous System and Neurooncology, University of Münster, Germany; 3Department of Neurology, Dallas VA Medical Center and UT Southwestern Medical Center, Dallas, Texas, USA

Abstract: Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.

Keywords: immunosuppressant, oral drugs, risk–benefit, safety






 

Other articles by Professor Bernd Kieseier



Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Review of teriflunomide and its potential in the treatment of multiple sclerosis
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Erratum
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model
Erratum
RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University